J
Jana Markova
Researcher at Charles University in Prague
Publications - 97
Citations - 3144
Jana Markova is an academic researcher from Charles University in Prague. The author has contributed to research in topics: BEACOPP & ABVD. The author has an hindex of 22, co-authored 86 publications receiving 2690 citations. Previous affiliations of Jana Markova include Czech Hydrometeorological Institute.
Papers
More filters
Journal ArticleDOI
Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group
Peter Borchmann,Heinz Haverkamp,Volker Diehl,Thomas Cerny,Jana Markova,Anthony D. Ho,Hans-Theodor Eich,Hans Konrad Mueller-Hermelink,Lothar Kanz,Richard Greil,Andreas Rank,Ursula Paulus,Lenka Šmardová,Christoph Huber,Bernd Dörken,Christoph Nerl,Stefan W. Krause,Rolf-Peter Mueller,Michael Fuchs,Andreas Engert +19 more
TL;DR: The HD12 study as discussed by the authors showed that eight cycles of BEACOPPescalated was compared with four cycles of baseline dose, and RT with no RT in the case of initial bulk or residual disease.
Journal ArticleDOI
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial
Karolin Behringer,Helen Goergen,Felicitas Hitz,Josée M. Zijlstra,Richard Greil,Jana Markova,Stephanie Sasse,Michael Fuchs,Max S. Topp,Martin Soekler,Stephan Mathas,Julia Meissner,Martin Wilhelm,Peter Koch,Hans-Walter Lindemann,Enrico Schalk,Robert Semrau,Jan Kriz,Tom Vieler,Martin Bentz,Elisabeth Lange,Rolf Mahlberg,Andre Hassler,Martin Vogelhuber,Dennis Hahn,Jörg Mezger,Stefan W. Krause,Nicole Skoetz,Boris Böll,Bastian von Tresckow,Volker Diehl,Michael Hallek,Peter Borchmann,Harald Stein,Hans Theodor Eich,Andreas Engert +35 more
TL;DR: Non-inferiority of the experimental variants compared with ABVD in terms of freedom from treatment failure (FFTF) is shown by excluding a difference of 6% after 5 years corresponding to a hazard ratio (HR) of 1.72, via a 95% CI.
Journal ArticleDOI
Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma.
Boris Böll,Henning Bredenfeld,Helen Görgen,Teresa Halbsguth,Hans Theodor Eich,Martin Soekler,Jana Markova,Ulrich Keller,Ullrich Graeven,Stephan Kremers,Michael Geissler,Guido Trenn,Michael Fuchs,Bastian von Tresckow,Dennis A. Eichenauer,Peter Borchmann,Andreas Engert +16 more
TL;DR: PVAG is safe and feasible in elderly HL patients, and the 3-year estimates for overall survival and progression-free survival were 66% and 58% (95% CI, 43%-71%), respectively.
Journal ArticleDOI
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group
Peter Borchmann,Heinz Haverkamp,Andreas Lohri,Ulrich Mey,Stefanie Kreissl,Richard Greil,Jana Markova,Michaela Feuring-Buske,Julia Meissner,Ulrich Dührsen,Helmut Ostermann,Ulrich Keller,Georg Maschmeyer,Georg Kuhnert,Markus Dietlein,Carsten Kobe,Hans Theodor Eich,Christian Baues,Harald Stein,Michael Fuchs,Volker Diehl,Andreas Engert +21 more
TL;DR: This open-label, international, randomised, phase 3 study aimed to assess whether intensifying standard chemotherapy (BEACOPPescalated) by adding rituximab would improve progression-free survival in patients with positive PET after two courses of chemotherapy.
Journal ArticleDOI
Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia
Jana Markova,Petra Michková,Kateřina Burčková,Jana Březinová,Kyra Michalova,Alena Dohnalova,Jacqueline Maaloufová,Petr Soukup,A Vítek,Petr Cetkovský,Jiří Schwarz +10 more
TL;DR: It is confirmed that patients with DNMT3A mutations relapse more often and have inferior OS when only patients achieving CR are analyzed, and ‘Double‐mutated’ patients have a very poor prognosis.